Showing results (181-190 of 330) with videos related to
Sort By:
Pageof 33
Journal of Gastroenterology|March 9, 2019
Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in JapanKoichi Takaguchi, Hidenori Toyoda, Akemi Tsutsui, et al.Hepatology Communications|October 22, 2021
Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C VirusNobuharu Tamaki, Masayuki Kurosaki, Yutaka Yasui, et al.Diagnostics (Basel, Switzerland)|August 14, 2020
Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver DiseaseYoshio Sumida, Masashi Yoneda, Yuya Seko, et al.Oncotarget|May 21, 2017
Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysisMirko Dengler, Katharina Staufer, Heidemarie Huber, et al.Cancer Medicine|May 24, 2022
The prognosis of elderly patients with hepatocellular carcinoma: A multi-center 19-year experience in JapanTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.Oncology|August 20, 2024
Factors Affecting an Increase in Spleen Volume and Association of Spleen Volume Variation with the Clinical Outcomes of Atezolizumab and Bevacizumab Treatment for Hepatocellular Carcinoma: A Retrospective AnalysisTakeshi Hatanaka, Naoto Saito, Satoru Kakizaki, et al.Journal of Medical Virology|June 25, 2021
Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study GroupToshifumi Tada, Masayuki Kurosaki, Shinichiro Nakamura, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 30, 2024
Kinetics of the hepatitis B core-related antigen and treatment responses in chronic hepatitis B patients treated with tenofovir alafenamideNorio Itokawa, Masanori Atsukawa, Akihito Tsubota, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 7, 2022
Usefulness of neutrophil-to-lymphocyte ratio in predicting progression and survival outcomes after atezolizumab-bevacizumab treatment for hepatocellular carcinomaHironori Ochi, Masayuki Kurosaki, Kouji Joko, et al.Investigational New Drugs|August 30, 2024
Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinomaNami Mori, Nobuharu Tamaki, Shintaro Takaki, et al.Pageof 33